Glaukos Corporation, a company specializing in the development and commercialization of surgical and pharmaceutical therapies designed to treat glaucoma, corneal disorders, and retinal diseases, has reported an insider transaction. Joseph Gilliam, the President & COO of Glaukos Corp (GKOS), sold 4,890 shares of the company on January 16, 2024, according to a recent SEC Filing.
Over the past year, the insider has sold a total of 74,799 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed within the company, where there have been 25 insider sells and no insider buys over the past year.
On the date of the sale, shares of Glaukos Corp were trading at $89.17, giving the company a market capitalization of $4.431 billion. The transaction has contributed to the ongoing discussion about the stock's valuation in the market.
According to the GuruFocus Value, which is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates, Glaukos Corp has a GF Value of $57.88. With the stock trading at $89.17, the price-to-GF-Value ratio stands at 1.54, indicating that the stock is significantly overvalued based on its GF Value.
Investors and analysts often monitor insider transactions as they can provide insights into the company's performance and insider perspectives on the stock's value. The recent sell-off by the insider at Glaukos Corp may attract attention from the market, especially considering the stock's current valuation relative to the GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
